Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sorrento Therapeutics Inc.

www.sorrentotherapeutics.com

Latest From Sorrento Therapeutics Inc.

Novartis Touts Ligelizumab As Xolair Successor In CSU

Novartis and Roche's Xolair was approved as a treatment for hives in 2014 and has transformed treatment for patients with severe symptoms. New data on the former's new IgE inhibitor suggest that a more effective drug could be on the way.

Dermatology Clinical Trials

Sorrento’s Partner Mabpharm Files For Infliximab In China

Banking on the burgeoning biosimilars approvals in China, Sorrento’s partner Mabpharm has filed in China for an infliximab biosimilar. Sorrento plans to follow this up with a US filing for a ‘biobetter’ version via the BLA route in 2020.

China Biosimilars

Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Deals Business Strategies

Sorrento Resists M&A Frenzy

Two pharma companies have made an offer for Sorrento Therapeutics that could triple the pain management and immune-oncology specialist's value but the San Diego-based group is holding firm.

M & A Business Strategies
See All

Company Information

UsernamePublicRestriction

Register